2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Related Posts

Continuous Glucose Monitoring and Mortality Risk Among U.S. Veterans Receiving Dialysis With Diabetes

Narasaki Y, Kalantar-Zadeh K, Zisman-Ilani Y, Klonoff DC, Kovesdy CP, Li Z, Jin A, Crowley S, M Belcher J, Gee P, Gin GE, Jordan M,[...]

Deep learning-based CT-derived vertebral bone mineral density and metformin therapy: a longitudinal study in the Multi-Ethnic Study of Atherosclerosis

Momtazmanesh S, Hathaway QA, Jannatdoust P, Ghotbi E, Bancks MP, Bluemke DA, Barr RG, Smith BM, Post WS, Budoff MJ, Lima JAC, Demehri S. Deep[...]

Racial and Ethnic Disparities in Living Donor Kidney Transplantation in California: 2010-2024

Al Ammary F, Adeyemo S, Lincoln KD, Ku E, Adey DB, Lau WL, Rhee CM, Kalantar-Zadeh K, Flores GM. Racial and Ethnic Disparities in Living[...]